Australian Clinical Labs Ltd
ASX:ACL
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
2.16
3.8
|
| Price Target |
|
We'll email you a reminder when the closing price reaches AUD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Australian Clinical Labs Ltd
Australian Clinical Labs Ltd
Cash & Cash Equivalents
Australian Clinical Labs Ltd
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Australian Clinical Labs Ltd
ASX:ACL
|
Cash & Cash Equivalents
AU$26.1m
|
CAGR 3-Years
-9%
|
CAGR 5-Years
45%
|
CAGR 10-Years
N/A
|
|
|
Healthia Ltd
ASX:HLA
|
Cash & Cash Equivalents
AU$5.6m
|
CAGR 3-Years
10%
|
CAGR 5-Years
50%
|
CAGR 10-Years
N/A
|
|
|
Sonic Healthcare Ltd
ASX:SHL
|
Cash & Cash Equivalents
AU$645m
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
11%
|
|
|
Integral Diagnostics Ltd
ASX:IDX
|
Cash & Cash Equivalents
AU$42.4m
|
CAGR 3-Years
-12%
|
CAGR 5-Years
15%
|
CAGR 10-Years
N/A
|
|
|
Capitol Health Ltd
ASX:CAJ
|
Cash & Cash Equivalents
AU$24.1m
|
CAGR 3-Years
3%
|
CAGR 5-Years
27%
|
CAGR 10-Years
10%
|
|
|
H
|
Healius Ltd
ASX:HLS
|
Cash & Cash Equivalents
AU$60.1m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
8%
|
|
Australian Clinical Labs Ltd
Glance View
Australian Clinical Labs Ltd. provides pathology services. The company is headquartered in Melbourne, Victoria and currently employs 2,794 full-time employees. The company went IPO on 2021-05-14. The firm is engaged in private hospital pathology businesses in regions of Western Australia, Victoria, South Australia and the Northern Territory. Its brands include Australian Clinical Labs, SunDoctors, Helix Pathology, Southern Sun, BeFunctional Labs and Gribbles Veterinary Pathology. The Australian Clinical Labs provides pathology in Australia, servicing clinicians, patients, hospitals, commercial clients and public organizations. The SunDoctors offers diagnosis and treatment of skin cancer. The Helix Pathology delivers specialized histopathology and cytology testing services. The Southern Sun is the skin cancer lab and the commercial lab in Australia. The BeFunctional Labs assists practitioners in the diagnosis, treatment and management of patients by providing functional pathology tests. The Gribbles Veterinary Pathology provides animal health professionals with pathology service.
See Also
What is Australian Clinical Labs Ltd's Cash & Cash Equivalents?
Cash & Cash Equivalents
26.1m
AUD
Based on the financial report for Jun 30, 2024, Australian Clinical Labs Ltd's Cash & Cash Equivalents amounts to 26.1m AUD.
What is Australian Clinical Labs Ltd's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
45%
Over the last year, the Cash & Cash Equivalents growth was 31%. The average annual Cash & Cash Equivalents growth rates for Australian Clinical Labs Ltd have been -9% over the past three years , 45% over the past five years .
You don't have any saved screeners yet
